Thank you, Mr. Chair.
Thank you, Mr. Tada and Ms. Marquis, for being with us.
Mr. Tada, critics of the deal may be concerned that this deal lost money, but that is not true. We saw the evolution of a vaccine from scratch. We saw the growth of a sector and the development of a talent pipeline.
Can you speak a little bit about what the values of the investment in Medicago were and the importance of the government participating in de-risking these kinds of investments?